Friday, 25 September 2026European Markets
ExploreSearch
ViaNews EU
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· March 5, 2026

Alliance for Genomic Discovery expands with Regeneron Genetics Center membership and new proteomics data offering

View original at finance.yahoo.com
Alliance for Genomic Discovery expands with Regeneron Genetics Center membership and new proteomics data offering Dataset grows to more than 312,000 whole genomes with longitudinal clinical data GSK is one of the first to lead a further expansion of 50,000 whole genomes paired with proteomic data SAN DIEGO, March 5, 20…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • There is proven value in the integration of proteomics and comprehensive datasets, evidenced by the boon of large-scale studies showing promise in pinpointing drug targets linked to human disease

    80% confidence

  • Integrating high-quality clinical and genomic data with advanced AI will help pharma translate discoveries into meaningful advances for patients

    80% confidence

  • The AGD dataset is among the largest collections of whole genome sequences available, and it is the world's largest pairing of whole genome sequences with the depth of clinical data that comes from a leading academic medical center

    80% confidence

  • Vanderbilt has an exceptional biobank and population-scale genetics program — one of the most impressive in the world

    80% confidence

  • AGD has already enabled disease-impacting discoveries in autoimmune disease and obesity, with many more such studies underway, and continued expansion accelerates this progress

    80% confidence

  • Human genetics is the most powerful compass we have for finding the right targets and delivering the best innovative medicines

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Enterprise AI Agents Scale Up Through Partnerships and Funding, But Data Readiness Lags Ambition
A wave of vertical AI-agent startups (Swarm, Veridox, Avallon AI, DA2, F2, Earthian, Meanwhile, Covecta, Penguin AI, Maisa AI) is being funded and profiled just as major infrastructure players — Microsoft/Mistral, Siemens/NVIDIA, and Manulife/Microsoft — cement enterprise AI governance and compute partnerships. Yet a Google Cloud report shows AI agents still lack access to the majority of company data (only 45% on average), and insider selling at incumbent C3.ai signals investor caution even as adoption intent (100% planned agentic AI use within two years) races ahead of actual data infrastructure.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Berkshire Hathaway
Both facts report Berkshire Hathaway's cash position on 2026-01-01 with identical observation timestamps, but claim vastly different values: 380 billion USD vs 400 USD. These cannot both be true for the same entity at the same point in time. The magnitude of the discrepancy (a factor of ~10^9) rules out rounding, unit conversion, or methodological differences.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,984
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,984 facts checked against source5,306 source documents archived
Query this data → isubstrate.com
Alliance for Genomic Discovery expands with Regeneron Genetics Center membership and new proteomics data offering — Source | Via News | ViaNews EU